Cyclooxygenase-3 (COX-3): Filling in the gaps toward a COX continuum?
- 8 October 2002
- journal article
- editorial
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 99 (21) , 13371-13373
- https://doi.org/10.1073/pnas.222543099
Abstract
No abstract availableThis publication has 38 references indexed in Scilit:
- The Spinal Phospholipase-Cyclooxygenase-Prostanoid Cascade in Nociceptive ProcessingAnnual Review of Pharmacology and Toxicology, 2002
- Pharmacology of cyclooxygenase-2 inhibition in the kidneyKidney International, 2002
- Cyclooxygenase-2: A Therapeutic TargetAnnual Review of Medicine, 2002
- ParacetamolClinical Journal of Sport Medicine, 2000
- Cyclo‐oxygenase‐2: pharmacology, physiology, biochemistry and relevance to NSAID therapyBritish Journal of Pharmacology, 1999
- Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitorBritish Journal of Pharmacology, 1997
- Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agentsNature, 1996
- Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2Nature Structural & Molecular Biology, 1996
- From studies of biochemical mechanism to novel biological mediators: Prostaglandin endoperoxides, thromboxanes, and leukotriencesBioscience Reports, 1983
- Inhibition of Prostaglandin Synthetase in Brain explains the Anti-pyretic Activity of Paracetamol (4-Acetamidophenol)Nature, 1972